Compulsory Licences Needed For Affordable Hepatitis C Innovative Drug Regimens

Compulsory licences should be issued to roll out generic versions of innovative HCV drugs. Only generic competition can push down the extortionate prices of these lifesaving medicines, while placing equitable access and public interest before monopolistic pharma companies’€™ business strategies

Compulsory Licences Needed For Affordable Hepatitis C Innovative Drug Regimens

by  Daniele Dionisio

Member, European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases

A leading cause of liver cancer and cirrhosis, infection by hepatitis C virus (HCV) affects at least 185 million people worldwide, 85% of whom live in low (13%)- and middle (72%)-income countries. Around 15% of Egypt’€™s population, for example, is infected -the world’€™s highest prevalence – while it is estimated that 12 million people in India have hepatitis C.

 Nearly 350,000 people are killed by hepatitis C yearly, where  preventive vaccines are lacking.

And this occurs at a time when at least 1.2 million people in Japan and three million Americans suffer from hepatitis C, while the infection is a major European public-health challenge (between 0.4% and 3.5% of the population in different EU Member States) as the most common single cause of liver transplantation.

Up to last year, the success rate of available treatments was poor, with a ribavirin-interferon combination being effective in less than 50% of patients after a year (while being fraught with important side effects), and directly acting newer drugs not exceeding 75% sustained response without fully eliminating the need for ribavirin-interferon therapy.

But in recent months innovative medicines have been approved that can cure most HCV infections and do not require interferon in many cases. By directly blocking essential steps for HCV to replicate, they have shown convincing efficacy, mainly when used in combination (functional cure rates in excess of 90% after 12 week treatment), with a good safety profile. These medicines include Bristol-Myers Squibb daclatasvir(Daklinza®), Gilead sofosbuvir (Sovaldi®), Janssen simeprevir (Olysio®), and Bristol-Myers Squibb asunaprevir (Sunvepra®).

And new entries are expected soon, now that big companies are increasingly engaged in bids and acquisition deals to procure new components for more effective, powerful combination regimens. As an example,  Merck will buy the biotechnology company Idenix Pharmaceuticals for $3.85 billion, aiming, as reported, to add a drug from Idenix to its own combination of two agents and develop a once-a-day pill for all C virus subtypes in as little as four week treatment.

Needless to say, the high prices the companies are paying for such endeavors will eventually be over-rewarded by the billions of dollars in annual sales a successful drug regimen could secure. Purportedly , Sovaldi® already helped Gilead rake in, since its debut last December, about $2.3 billion in the first three months of this year, in compensation of $11 billion the company spent  in 2011 to obtain the rights tosofosbuvir through its acquisition of Pharmasset.

Good news for big pharma profits, these circumstances turn into bad news when it comes to prices the manufacturers apply for a 12-week course of each breakthrough regimen. Nothing less than scandalous,estimated prices, averaging from $133,000 to $200,000 for a two-drug new combination regimen (against trifling production costs!), definitely impair affordability and put these drugs beyond the grasp of most of the 90% of hepatitis C patients in low- and middle-income countries where a 12-week course of treatment should cost no more than $500, as firmly believed by Médecins Sans Frontières.

What’€™s more, following inclusion of these drugs in April 2014 WHO treatment guidelines for hepatitis C virus, the cost issue has become all the more critical for national budgets in the resource-limited and affluent countries as well.

As such, it comes as no surprise that, according to allowances in India’€™s Patent Law as regards lack of real innovation, oppositions  were recently filed with the competent authority in India against granting  Sovaldi®  a patent.

As an effect of the mounting pressure against prices out-of-reach for national health insurances, big pharma has begun negotiating bilateral agreements and voluntary licence (VL) deals with country governments and generic manufacturers. In the Gilead cases with Egypt and India, Sovaldi® has been priced at $900 for a 12-week course, and negotiations are in progress with Indian manufacturers to produce generic sofosbuvir.

Unfortunately, as reported, while the price agreed with Egypt would rank beyond the reach of the domestic health budget, voluntary licence negotiations with India are feared to exclude export to many middle-income countries with high HCV burden.

Likely, this is not happening by chance at a time when international donors are cutting support to middle-income economies and the brand industry is eagerly looking to the fast-growing markets where a number of well-off elites, who can afford out-of-pocket spending (at least 300 million people in India, 800 million in China), now live.

Admittedly, although VLs, as part of the flexibilities laid down in the World Trade Organization TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement, do include permission for export, a number of constraints limit this model basically because the originators actually hold control over the whole manufacturing, distribution and pricing chain of steps: an unbalanced mechanism.

On the contrary, unrestrained competition by compulsory licences (CLs), another flexibility provision in TRIPS, would be a far better mechanism for maximizing the affordability by allowing “…someone else to produce the patented product or use the patented process without the consent of the patent holder”€. 

This would also be the case for an allowance for export agreed upon through a 2003 WTO waiver (the “€œAugust 30th Decision”€) that permits export under CLs to countries unable to manufacture key medicines themselves.

On these grounds, compulsory licences should be issued at once to roll out generic versions of innovative HCV drugs. Only generic competition would be up to pushing down the extortionate prices of these lifesaving medicines, while making equitable access and public interest overcome monopolistic pharma companies’€™ business strategies.

To the point, cheap generic versions of state-of-the-art HCV drugs would reasonably be within reach. Relevantly, published data this year argue that generic-drug makers would be able to roll out these medicines at $100-€“250 for a 12-week course.

Overall, these considerations align with a resolution on hepatitis unanimously adopted by Member States at WHO General Assembly in May.

Among others, the resolution urges Member States …(12) to consider, as necessary, national legislative mechanisms for the use of the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights in order to promote access to specific pharmaceutical products;…

The resolution also requests the Director General  (9) to support Member States with technical assistance in the use of trade-related aspects of intellectual property rights (TRIPS) flexibilities when needed, in accordance with the global strategy and plan of action on public health, innovation and intellectual property;…

  

————————————————————————————

*Article republished from Intellectual Property Watch August 5, 2014 http://www.ip-watch.org/2014/08/05/compulsory-licences-needed-for-affordable-hepatitis-c-innovative-drug-regimens/  

Daniele Dionisio is a member of the European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases. He is an advisor for “€œMedicines for the Developing Countries”€ for the Italian Society for Infectious and Tropical Diseases (SIMIT), and former director of the Infectious Disease Division at the Pistoia City Hospital (Italy). He may be reached at d.dionisio@tiscali.it  https://twitter.com/DanieleDionisio 

 

News Link 107

 

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries

 

News Link 107

WHO conference on health and climate 

Call for ‘ecohealth’ approach to tackling climate change 

Desperately seeking scale as ‘pilots to nowhere’ on the rise 

Counting Down to a New Era of Global Health 

UHC and the post-2015 debate: what if we started conceiving health in a society as an emergent property? 

Oxfam: How we fight poverty 

Stopping Disease With A Simple Innovation: New Floors 

Do we really need a new drug or vaccine for Ebola? 

Ebola May Leave 1 Million People In Need Of Food Help 

How to Stop Ebola — and the Next Outbreak   

Ebola in West Africa: Four Questions for the U.S. Response Going Forward   

Opportunities in Africa – Investing Across Sectors 

Great future for U.S.-Africa trade  

Urban Development in Sub-Saharan Africa: Bearer of Goods and Risks

Nutrition: there’s no quick fix for hunger or obesity   

Food security and Rodrik’s trilemma  

DNDi’s  annual report 2013 

10 Big Ideas for Making Energy Efficiency Bankable in India  

Elderly in India  

A Critical New Role for the World Bank 

Briefing: What next for Uganda’s anti-gay law?

Commission moves to tighten customs security 

How the Medicines Patent Pool can help to overcome patent-related constraints on new ARVs to … 

 

 

 

News Link n. 106

 

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries

 

News Link 106

International Regulation of Pharmaceuticals: Codification by Means of Legal Transplantation  

UN declares Ebola outbreak global ‘international public health emergency’ 

Gaza-Israel conflict: Disregard for humanitarian law led to unacceptable toll on civilians  

EU launches new programme to support Africa’s continental integration 

EU to provide new funding to counter organised crime and drug trafficking  

“Unitary patent“ and court system – The oral hearing on Spain’s actions at the CJEU 

EU finalises free trade agreement with Canada 

Analyst: Agriculture remains an obstacle to EU-Mercosur pact 

Eight ways to end Aids within a generation 

The end of AIDS: Possibility or pipe dream? A tale of transitions 

Can innovation drive HIV responses to meet 90:90:90 targets by 2020? 

Is PrEP Cost-Effective?  

PEPFAR Pediatric HIV treatment partnership targets antiretroviral access gap  

Opinion: The US-Africa summit – a missed opportunity

Can the US and China Cooperate on Development in Africa? 

10 Ways the Obama Administration Can Tackle Hunger in Africa 

Public private partnerships key to ensuring food security  

Global Medical Students Call For Shift To Health Over Trade, R&D 

Italy overhauls its development cooperation system in search for a fresh start   

The World Bank Can’t Sacrifice the Poor to Stay in the Game 

World Bank safeguards: Pushing more money out the door at the expense of the poor?  

The solutions to tackle global challenges are within our grasp 

 

News Link n. 105

 

The news links are part of the research project GESPAM (Geopolitica, Salute Pubblica e Accesso alle Medicine/Geopolitics, Public Health and Access to Medicines), which aims to focus on the best options for the use of trade and government rules related to public health by resource-limited countries

 

News Link 105

Hepatitis C annual report: progress made, but much more to do 

Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond  

Uganda Anti-Gay Law Struck Down by Court 

Court ruling over anti-gay law ‘fragile gain’ for anti-HIV aid in Uganda 

Sweden resumes aid to Uganda after suspending it over anti-gay law 

Aid agencies request US$ 369 million to meet urgent needs in Gaza and call for safe access  

The 2014 WHO conference on health and climate 

Recycling fuel subsidies as health subsidies

Reframing climate change as a health issue 

Bringing air pollution into the climate change equation 

How to Achieve the Millennium Development Goals 

MAINSTREAMING GENDER IN HIV & AIDS WORK 18-19 September 2014, Protea Hotel O.R. Tambo Airport, Johannesburg 

The Brics have a chance to succeed where the World Bank has failed 

Land Grabbing – A New Political Strategy for Arab Countries   

Family planning and the post-2015 development agenda

Physical growth of children and adolescents in China over the past 35 years 

It’s high time India stands up for its malnourished children 

WHO on Ebola outbreak: We need more health workers   

Ebola  outbreak: US experts to head to West Africa 

Disparities In Access To Palliative Care